Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration

Tempest Therapeutics, Inc.

CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.
Consulting agreements are one-year, hourly compensation; executives retain their roles and responsibilities.
Separation agreements provide full acceleration of all outstanding equity awards, vested immediately on June 5, 2025.
Extended post-Transition exercise period to earlier of Change of Control or 180 days after separation.
Transition part of previously announced process to explore strategic alternatives and extend capital resources.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.